Moonwalk Biosciences
Moonwalk Biosciences is a preclinical biotech developing precision epigenetic medicines for obesity and cardiometabolic disease, coupling its EpiRead methylome-mapping and EpiWrite epigenetic-editing platforms (now pivoting toward siRNA) with an AI-driven adipose-biology discovery engine.
- Company typePrivate
- Founded2024
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Moonwalk Biosciences does
Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision medicines that target the epigenome — the regulatory layer above DNA — rather than the DNA sequence itself. The company couples two proprietary platforms: EpiRead, which performs whole-genome, high-resolution single-cell mapping of DNA methylation across healthy and diseased cell states, and EpiWrite, a modular non-DNA-cutting toolkit that applies targeted methylation modifications to activate or suppress genes, demonstrated to perform seven simultaneous multiplexed edits at >85% efficiency in primary human cells. An AI layer built around a proprietary Transformer model called Methylencoder, combined with the first genome-wide epigenetic atlas of human adipose tissue, is used to predict and validate novel therapeutic targets.
The company's pipeline comprises seven preclinical candidates (MW01 through MW09) addressing obesity and cardiometabolic disease through adipose-biology mechanisms including lipolysis, thermogenesis, adipogenesis, adipose endocrine function, and energy homeostasis; MW01 is the most advanced in IND-enabling studies with NHP pharmacodynamic data expected in early 2027. In February 2026, the company publicly shifted its lead modality toward siRNA-based obesity therapeutics while retaining its adipose-biology discovery engine and epigenetic expertise.
The business model is licensing- and partnership-oriented: as a private, venture-backed preclinical company Moonwalk has no commercial revenue and no product pricing. It was launched in January 2024 with $57 million in combined seed and Series A financing led by Alpha Wave Ventures with ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The company is co-founded by Feng Zhang (CRISPR pioneer, Broad Institute/MIT), Alex Aravanis (former CTO of Illumina and co-founder of GRAIL), Arash Jamshidi (former SVP Data Sciences at GRAIL), and Justin Valley (former VP at Berkeley Lights), and operates from South San Francisco and San Diego with a headcount in the 11–50 range.
Moonwalk Biosciences firmographics
Firmographics- Name
- Moonwalk Biosciences
- Legal name
- Moonwalk Biosciences, Inc.
- Website
- https://moonwalk.bio
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Moonwalk Biosciences is a preclinical biotech developing precision epigenetic medicines for obesity and cardiometabolic disease, coupling its EpiRead methylome-mapping and EpiWrite epigenetic-editing platforms (now pivoting toward siRNA) with an AI-driven adipose-biology discovery engine.
- Ownership category
- akta.pro rank
Moonwalk Biosciences industry classification
Industry- Product category
- Epigenetic Therapeutics — Cardiometabolic Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Keywords
Where Moonwalk Biosciences is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Moonwalk Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Epigenetic therapeutic pipeline development: As a preclinical stage biotechnology company, Moonwalk Biosciences is in the drug discovery phase with no commercial revenue. The company is developing a pipeline of epigenetic therapeutics for cardiometabolic diseases (obesity, liver disease). Financing has come from venture capital investors including Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Moonwalk Biosciences product offering
Product offeringCore offering
Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision epigenetic medicines for cardiometabolic diseases, principally obesity and liver disorders. Its core offering is the integrated EpiRead™ epigenetic profiling and EpiWrite™ epigenetic engineering platform, which enables AI-guided target discovery and a pipeline of preclinical drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting adipose biology. The company also recently announced a strategic shift toward siRNA-based obesity therapeutics.
Product overview
Moonwalk Biosciences is a preclinical stage biotechnology company pioneering precision epigenetic medicines through its integrated EpiRead™ and EpiWrite™ platform technologies. EpiRead™ provides whole genome, high-resolution single-cell mapping of the methylome, while EpiWrite™ offers targeted methylation modifications through a modular non-DNA cutting toolkit capable of seven simultaneous multiplexed edits. The company leverages AI for epigenetic target prediction and is advancing a pipeline of siRNA-based drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting obesity and cardiometabolic diseases through diverse adipose mechanisms including lipolysis, thermogenesis, adipogenesis, and energy homeostasis.
Differentiator
Problem solved
Functional benefit
Products and services
- EpiRead™ Epigenetic profiling platform providing whole-genome, high-resolution single-cell mapping of the methylome, offering the most complete view of the epigenome in health and disease for internal drug discovery use.
- EpiWrite™ Epigenetic engineering platform using a modular non-DNA-cutting toolkit for targeted methylation modifications enabling gene activation and suppression, capable of seven simultaneous multiplexed edits at >85% efficiency in primary human cells.
- MW01 Obesity drug candidate targeting lipolysis and lipid droplet regulation; currently in IND-enabling stage.
- MW02 Obesity drug candidate targeting thermogenesis and brown/beige pathways; currently in preclinical candidate stage.
- MW03 Obesity drug candidate targeting adipogenesis and differentiation; currently in preclinical stage.
- MW05 Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.
- MW08 Lipid-lowering drug candidate targeting adipose endocrine function; currently in discovery stage.
- MW09 Obesity drug candidate targeting energy homeostasis; currently in discovery stage.
- MWₙ Additional pipeline targets and combinations under testing for obesity and other indications; currently in target validation stage.
Quantifiable outcome
- Seven simultaneous multiplexed edits at >85% efficiency for all seven edits in primary human cells
- +1 more outcomes
Companies that use Moonwalk Biosciences
Customer profileSegments2 records
Ideal customer profiles2 records
Moonwalk Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Moonwalk Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cardiometabolic Advisory BoardcoreWorld-class advisory board composed of five leading scientific and clinical experts: Paul Cohen (Rockefeller University), Silvia Corvera (UMass Chan Medical School), Michael Czech (UMass Chan Medical School), Shingo Kajimura (Harvard Medical School, HHMI Investigator), Rohit Loomba (UCSD). They bring expertise in adipocyte and liver biology to guide research programs.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Moonwalk Biosciences competitors and assessment
Company assessmentDirect peers
- Chroma Medicine: Chroma Medicine is a direct peer developing a single-platform epigenetic editing approach using engineered chromatin regulators and CRISPR-derived systems to tune gene expression without altering DNA sequence. Highly comparable to Moonwalk's EpiWrite platform, both targeting the same epigenetic medicines opportunity.
- Tune Therapeutics: Tune Therapeutics is a direct peer pioneering epigenetic gene silencing and programming using a single-platform approach. Highly comparable to Moonwalk's epigenetic editing vision and competes in the same target space of durable, non-DNA-altering gene regulation.
- Prime Medicine: Prime Medicine develops prime editing therapies, a next-generation gene editing modality. As a direct peer in the gene/epigenetic editing space with similar founder pedigree (David Liu), they compete for talent, capital, and partnership economics in precision genetic medicines.
- Verve Therapeutics: Verve Therapeutics is a direct peer pioneering in vivo gene editing for cardiovascular disease, founded out of David Liu's lab. Highly comparable in cardiometabolic disease targeting and the broader precision gene editing platform race.
- Beam Therapeutics: Beam Therapeutics is a direct peer in precision genetic medicines, founded by Feng Zhang, David Liu, and Jinke Cheng. Beam is also co-founded by Moonwalk's scientific co-founder Feng Zhang, making it both a peer and a portfolio-overlap reference for Moonwalk's investor base.
Emerging players
- Epicypher: Epicypher develops chromatin/epigenomics research tools and reagents. While not a therapeutic company, they overlap in epigenetic target ID, mapping, and chromatin biology — capabilities Moonwalk's EpiRead platform also pursues.
- Korro Bio: Korro Bio is an emerging player in RNA editing for genetic diseases, sharing Moonwalk's precision nucleic acid approach and operating with a similar early-stage platform-to-pipeline model. Comparable in stage, technology paradigm, and target ambition.
- Metagenomi: Metagenomi is an emerging precision gene editing company developing a broad toolbox of editing modalities (CRISPR-derived and novel). Comparable as a platform-to-pipeline biotech in the broader genetic medicines space where Moonwalk operates.
Broad incumbents
- Alnylam Pharmaceuticals: Alnylam is the established leader in RNAi/siRNA therapeutics. Following Moonwalk's Feb 2026 pivot to siRNA obesity therapies, Alnylam is the most relevant reference for the modality's clinical validation, delivery technology (GalNAc), and partnership economics.
- Arrowhead Pharmaceuticals: Arrowhead is an established siRNA therapeutics company with a broad pipeline including cardiometabolic and liver-targeted programs. Following Moonwalk's pivot, Arrowhead is a key reference for siRNA-based obesity and liver disease development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Moonwalk Biosciences social profiles
Digital presenceMoonwalk Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Moonwalk Biosciences leadership team
Management profileNumber of profiles
Profiles1 record
Moonwalk Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Moonwalk Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Moonwalk Biosciences
What does Moonwalk Biosciences do?
Moonwalk Biosciences is a preclinical-stage biotechnology company developing precision epigenetic medicines for cardiometabolic diseases, principally obesity and liver disorders. Its core offering is the integrated EpiRead™ epigenetic profiling and EpiWrite™ epigenetic engineering platform, which enables AI-guided target discovery and a pipeline of preclinical drug candidates (MW01, MW02, MW03, MW05, MW08, MW09, MWₙ) targeting adipose biology. The company also recently announced a strategic shift toward siRNA-based obesity therapeutics.
Is Moonwalk Biosciences a public or private company?
Moonwalk Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Moonwalk Biosciences founded?
Moonwalk Biosciences was founded in 2024. It employs 11 to 50 people.
Where is Moonwalk Biosciences based?
Moonwalk Biosciences is headquartered in South San Francisco, United States, in the North America region.
How does Moonwalk Biosciences make money?
One revenue line is on record: epigenetic therapeutic pipeline development.
Who are Moonwalk Biosciences's main competitors?
Direct peers on record are Chroma Medicine, Tune Therapeutics, Prime Medicine, Verve Therapeutics and Beam Therapeutics. Emerging players are Epicypher, Korro Bio and Metagenomi. Broad incumbents are Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals.
Does Moonwalk Biosciences have an API?
No public API is recorded for Moonwalk Biosciences.
What industry is Moonwalk Biosciences in?
Moonwalk Biosciences's product category is Epigenetic Therapeutics — Cardiometabolic Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.